Akèy › Kansè nan tete › North Carolina › Durham
Etid klinik pou Kansè nan tete nan Durham, NC
64 etid pou Kansè nan tete ap chèche patisipan nan sit nan ak bò kote Durham (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
The Vanguard Study: Testing a New Way to Screen for Cancer
Ap rekriteVolontè an sante akeyi
- Durham VA Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
A Study of PHST001 in Advanced Solid Tumors
Ap rekriteFaz 1
- Duke Cancer Institute, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ap rekriteFaz 1/2
- Duke University, Durham
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Ap rekriteFaz 3
- Duke Cancer Network, Durham
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Durham VA Medical Center, Durham
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
Ap rekriteFaz 2Volontè an sante akeyi
- University of North Carolina, Chapel Hill · 10 mi lwen
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
Ap rekriteFaz 2
- UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Radiation Therapy and Thymus Function in Young Women With Breast Cancer
Ap rekriteEtid obsèvasyon
- Duke Cancer Center, Durham
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Ap rekriteFaz 1
- Duke Cancer Center, Durham
Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- University of North Carolina, Chapel Hill · 10 mi lwen
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Ap rekriteFaz 2
- Duke Cancer Institute, Durham
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Ap rekriteFaz 3
- Clinical Trial Site, Durham
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Ap rekriteFaz 1
- Duke University Medical Center, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Ap rekriteFaz 3
- University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
Ap rekriteFaz 2
- University of North Carolina Medical Center, Chapel Hill · 10 mi lwen
Identifying Patterns in the Breath of Individuals With Breast Cancer
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Duke University Medical Cente, Durham
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mi lwen
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study
Ap rekriteEtid obsèvasyon
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Ap rekriteFaz 1/2
- Duke Cancer Institute, Durham
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Ap rekriteFaz 1
- Duke Cancer Institute, Durham
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Ap rekriteFaz 1/2
- Duke Cancer Institute, Durham
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Ap rekriteFaz 3
- Duke Cancer Institute, Durham
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Ap rekriteFaz 2
- Duke University, Durham
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Ap rekriteFaz 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi lwen
Molecular Residual Disease Assessment in a Representative Diverse Population of Patients With Early-stage Breast Cancer
Ap rekriteVolontè an sante akeyi
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
TReatment of ADC-Refractory Breast CancEr With Dato-DXd or T-DXd: TRADE DXd
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Optimizing Surgical Decisions in Young Adults With Breast Cancer
Ap rekrite
- Duke Cancer Institute, Durham
A Novel Approach Utilizing Organ Specific Age Proteomics
Ap rekriteEtid obsèvasyon
- University of North Carolina, Chapel Hill · 10 mi lwen
Weight Management After Cancer for Survivors in Rural Communities
Ap rekrite
- Duke University Medical Center, Durham
Behavioral Pain Intervention for Older Cancer Patients
Ap rekrite
- Duke Cancer Network, Durham
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Duke Cancer Institute, Durham
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Ap rekrite
- Duke University/Duke Cancer Center, Durham
DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
Ap rekriteFaz 2
- Duke University Medical Center, Durham
Planning Grant for TOPS for Breast Cancer Survivors
Ap rekrite
- Duke University, Durham
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Ap rekrite
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · 10 mi lwen
A Study of a Decision Tool for People Considering Breast Reconstruction Surgery
Ap rekrite
- Duke Cancer Institute (Data collection only), Durham
- Duke Cancer Institute (Data collection only), Durham
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Ap rekriteEtid obsèvasyon
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi lwen
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Ap rekriteFaz 3
- Duke University Medical Center, Durham
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Ap rekriteFaz 1
- University of North Carolina, Chapel Hill · 10 mi lwen
Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging
Ap rekriteFaz 2Volontè an sante akeyi
- The University of North Carolina, Chapel Hill · 10 mi lwen
VisR Ultrasound for Noninvasively Interrogating Stromal Collagen Organization in Women as a Breast Cancer Biomarker: Evaluation of Anisotropy in Cancer Patients
Ap rekriteEtid obsèvasyon
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Compare Adjuvant Monotherapy With Endocrine or Accelerated Partial Breast Irradiation After Lumpectomy
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
Promoting Resilience in Women With Breast Cancer (PRISM -MBC)
Ap rekrite
- University of North Carolina, Chapel Hill · 10 mi lwen
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
Ap rekriteFaz 2
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · 10 mi lwen
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Ap rekriteFaz 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease
Ap rekriteFaz 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers
Ap rekrite
- Duke University, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Ap rekriteFaz 1/2
- Duke Cancer Center/ DUMC, Durham
PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients
Ap rekriteEtid obsèvasyon
- UNC, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
Ap rekriteFaz 2
- University of North Carolina, Chapel Hill · 10 mi lwen
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Ap rekriteFaz 1
- Duke Cancer Institute, Durham
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
Ap rekrite
- UNC Cancer Hospital, Chapel Hill · 10 mi lwen
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
Ap rekrite
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Symptom Management and Transitioning to Engagement With Post-treatment Care for Adolescent and Young Adult Cancer Survivors
Ap rekrite
- Duke Cancer Institute, Durham
Feasibility of Symptom Management for Patients With Metastatic Breast Cancer to Increase Exercise
Ap rekrite
- Lineberger Comphrehensive Cancer Center at University of North Carolina at Chapel Hill, Chapel Hill · 10 mi lwen
BREAST Choice Decision Tool R21 - AIM2
Ap rekriteVolontè an sante akeyi
- The University of North Carolina, Chapel Hill · 10 mi lwen
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
Ap rekrite
- Duke University, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi lwen
UNC Pleural Fluid Registry
Ap rekriteEtid obsèvasyon
- UNC Lingeberger Comprehensive Cancer Center, Chapel Hill · 10 mi lwen
Etid Kansè nan tete nan lòt vil
- New York City, NY136 etid
- Houston, TX126 etid
- Boston, MA112 etid
- Nashville, TN81 etid
- Los Angeles, CA73 etid
- Edison, NJ68 etid
- St. Louis, MO64 etid
- Queens, NY64 etid
- Chicago, IL59 etid
- Philadelphia, PA56 etid
- Dallas, TX55 etid
- Arlington, VA47 etid
Lòt etid nan Durham
- Kansè (tout kalite)58 etid
- Kansè Poumon ki pa ti selil39 etid
- Myelom Miltip37 etid
- Leksemi mieloïd egi33 etid
- Kansè Metastatik33 etid
- Kansè pwostat32 etid
- Kansè poumon32 etid
- Kansè kolorektal28 etid
- Kansè ovè27 etid
- Lukemi lenfositè kwonik27 etid
- Ensifizyans kadyak26 etid
- Kansè pankreyas24 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.